RxDoctor Payments DataLook up a doctor →

Timothy Dorius, MD

Hematology & Oncology · Omaha, NENPI 1689961484

Payments from drug & device makers

$168,250in general payments, 2019–2025

Across 504 payments — averaging $333.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Napo Pharmaceuticals Inc$59K
  • GSK$35K
  • Genentech, Inc.$29K
  • AbbVie$19K
  • Gilead$12K
  • Mirati Therapeutics, Inc.$4K
  • plus $11K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Napo Pharmaceuticals Inc20$58,738
GSK18$34,947
Genentech, Inc.4$29,000
AbbVie15$18,527
Gilead(2 entities)28$12,199
Mirati Therapeutics, Inc.7$4,069
Pharmaessentia USA Corporation6$2,137
Seagen Inc.19$1,291
E.r. Squibb & Sons, L.L.C.43$818
Novartis20$608
Amgen19$392
Genentech USA, Inc.33$374
Pfizer19$333
Merck16$277
AstraZeneca(2 entities)10$266
Sanofi12$261
Johnson & Johnson(2 entities)14$255
Daiichi Sankyo Inc.11$251
Tersera Therapeutics LLC10$230
Eisai Inc.10$193
Lilly USA, LLC11$190
Bristol Myers Squibb11$177
Takeda Pharmaceuticals U.S.A., Inc.10$177
Pharmacyclics LLC, An Abbvie Company9$170
Incyte Corporation9$143
Bayer7$131
Karyopharm Therapeutics Inc.5$102
Boehringer Ingelheim4$97
Adaptive Biotechnologies Corporation5$94
Servier Pharmaceuticals LLC4$89
Kyowa Kirin, Inc.5$87
G1 Therapeutics, Inc.5$86
Pharmacosmos Therapeutics Inc.4$84
Array Biopharma Inc4$81
Myriad Genetic Laboratories, Inc.5$75
Regeneron Healthcare Solutions, Inc.3$74
Heron Therapeutics, Inc.4$72
Exelixis Inc.4$69
Taiho Oncology, Inc.4$68
Rigel Pharmaceuticals, Inc.3$55
Epizyme, Inc.3$54
AMAG Pharmaceuticals, Inc.3$52
Genmab U.S., Inc.2$52
Agios Pharmaceuticals, Inc.3$49
AVEO Pharmaceuticals, Inc.3$48
Blueprint Medicines Corporation3$45
Intera Oncology, Inc2$44
Dendreon Pharmaceuticals LLC2$44
Clovis Oncology, Inc.2$41
Octapharma USA, Inc.2$38
Deciphera Pharmaceuticals Inc.2$36
Astellas Pharma US Inc2$36
Dova Pharmaceuticals2$30
US Oncology Corporate, Inc.1$29
CTI Biopharma Corp.2$28
Pharming Healthcare, Inc.1$27
Foundation Medicine, Inc.2$26
Aurobindo Pharma USA, Inc.1$26
Coherus Oncology, Inc.1$24
Mylan Institutional Inc.1$18

How this compares

$168,250 in reported general payments places this provider in the 60th percentile of 73 hematology & oncology providers in Nebraska.

See all hematology & oncology providers in Nebraska →

Medicare billing

Part B allowed, 2024
$2,837,383
Medicare patients
405
Services billed
135,209

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Omaha

See the full list for Nebraska →

Where these figures come from

Is this you, or does something look wrong? →